NovaBridge Biosciences cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 21 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2019 | Dec2019 | Jun2020 | Sep2020 | Dec2020 | Jun2021 | Dec2021 | Jun2022 | Dec2022 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||
| Net Income | 49.46M | 166.65M | -15.05M | -27.56M | -8.22M | -162.42M | -16.32M | -8.94M | 2.28M | 10.84M | -3.15M | -5.50M | 6.83M | 72.86M | |||||||
| Share-based Compensation | 0.00M | 23.52M | 15.22M | 0.72M | 0.07M | 2.00M | 0.32M | 0.82M | 9.98M | 25.68M | 3.94M | 34.38M | |||||||||
| Deferred Taxes | -0.02M | -0.02M | |||||||||||||||||||
| Cash from Discontinued Operations | -30.64M | -33.64M | 26.46M | 7.84M | |||||||||||||||||
| Gains from Equity Investments | -0.03M | ||||||||||||||||||||
| Gains from Investment Securities | -0.00M | -1.30M | -1.98M | ||||||||||||||||||
| Cash from Operations | -30.64M | 153.34M | 8.42M | -10.95M | 1.84M | -14.60M | |||||||||||||||
| Depreciation, Depletion & Amortization | |||||||||||||||||||||
| Amortizatization of Intangibles | 0.20M | 0.41M | -0.81M | 0.18M | 0.19M | 0.20M | 0.20M | ||||||||||||||
| Amortization of Deferred Charges | 0.18M | 0.19M | 0.20M | 0.20M | |||||||||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.43M | 0.38M | 0.76M | 0.02M | 0.02M | 0.02M | 0.01M | ||||||||||||||
| Change in Working Capital | |||||||||||||||||||||
| Change in Accured Expenses | 22.16M | 0.28M | 28.87M | -0.24M | -3.31M | 8.64M | 10.71M | ||||||||||||||
| Other Working Capital Changes | -0.17M | -0.14M | -0.14M | -0.18M | -0.18M | -0.21M | -0.21M | ||||||||||||||
| Investing Activities | |||||||||||||||||||||
| Capital Expenditures | -1.08M | -0.67M | -0.49M | -0.00M | -0.04M | -0.15M | |||||||||||||||
| Change in Acquisitions & Divestments | 9.56M | 19.27M | 336.02M | 8.25M | 81.36M | ||||||||||||||||
| Cash from Investing Activities | 10.97M | -41.43M | 8.22M | -81.66M | -0.11M | ||||||||||||||||
| Financing Activities | |||||||||||||||||||||
| Other financing activities | 1.28M | -0.97M | 200.97M | ||||||||||||||||||
| Change in Capital Stock | |||||||||||||||||||||
| Shares Issued | 35.97M | 37.53M | 38.45M | ||||||||||||||||||
| Net Shares Issued and Repurchased | 0.01M | 0.42M | 0.39M | 0.93M | 19.21M | ||||||||||||||||
| Misc. | |||||||||||||||||||||
| Cash from Financing Activities | 16.07M | 280.56M | 127.47M | 60.75M | -3.02M | ||||||||||||||||
| Exchange Rate Effect | -8.86M | -3.23M | -17.61M | 0.60M | -0.01M | 0.07M | 275.91M | ||||||||||||||
| Change in Cash | -12.45M | 202.27M | 271.42M | -72.63M | -11.06M | 62.66M | -17.43M | ||||||||||||||
| Beginning Cash Balance | 736.45M | 526.06M | 552.67M | 475.37M | 310.67M | 310.67M | 310.67M | 68.26M | 68.26M | 68.26M | 210.63M | ||||||||||
| Free Cash Flow | -29.56M | 0.67M | 153.83M | 8.42M | -10.91M | 1.99M | -14.60M | ||||||||||||||
| Net Cash Flow | -3.60M | 239.14M | 289.03M | -73.23M | -11.06M | 62.59M | -17.62M |